×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| IPCA LABORATORIES LTD. | 17719.2 | 2620.4 | 17469.0 | 10.33 | 33,499 | 37.4 |
| Aster DM Healthcare Limited | 6514.7 | 805.9 | 6130.4 | 1.57 | 33103 | 93.6 |
| AJANTA PHARMA LTD. | 12491.9 | 2549.7 | 12085.6 | 20.4 | 32229 | 34.7 |
Ipca Laboratories Ltd., with Security Code 524494, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,401.6 | 1,488.7 | 1,662.7 | 1,506.8 | 1,510.6 | 1,565.9 | 1,810.9 | 1,662.7 | 1,638.4 | 1,746.9 |
| Expenses | 1,226.0 | 1,191.2 | 1,353.7 | 1,233.3 | 1,218.3 | 1,212.6 | 1,408.8 | 1,251.6 | 1,279.8 | 1,340.0 |
| Operating Profit | 175.6 | 297.5 | 309.0 | 273.5 | 292.3 | 353.2 | 402.1 | 411.1 | 358.6 | 406.9 |
| OPM % | 12.53% | 19.99% | 18.58% | 18.15% | 19.35% | 22.56% | 22.2% | 24.72% | 21.89% | 23.29% |
| Other Income | 33.5 | 43.2 | 36.1 | 16.9 | -79.2 | 15.4 | 17.0 | 17.4 | -260.1 | 25.0 |
| Interest | 17.7 | 30.8 | 38.6 | 27.2 | 24.1 | 19.4 | 17.3 | 10.2 | 16.2 | 12.1 |
| Depreciation | 59.2 | 60.4 | 61.4 | 63.0 | 61.8 | 61.3 | 62.7 | 62.8 | 65.2 | 63.1 |
| Profit before tax | 132.2 | 249.6 | 245.1 | 200.2 | 221.6 | 287.9 | 339.2 | 355.5 | 298.7 | 356.8 |
| Tax % | -35.8% | -33.3% | -33.9% | -31.6% | -49.1% | -29.1% | -28% | -24.7% | -479.3% | 26.5% |
| Net Profit | 84.8 | 166.6 | 162.1 | 136.9 | 64.8 | 204.1 | 244.1 | 267.6 | -65.1 | 262.0 |
| EPS in Rs | 3.34 | 6.57 | 6.39 | 5.4 | 2.55 | 8.05 | 9.62 | 10.55 | 0 | 10.33 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,546.0 | 1,511.6 | 1,587.6 | 2,034.0 | 2,052.9 | 2,033.0 | 2,092.6 | 2,354.9 | 2,245.4 | 2,246.7 |
| Expenses | 1,336.0 | 1,333.5 | 1,282.1 | 1,713.6 | 1,723.2 | 1,712.7 | 1,699.9 | 1,913.4 | 1,783.3 | 1,819.6 |
| Operating Profit | 210.0 | 178.1 | 305.5 | 320.3 | 329.7 | 320.3 | 392.7 | 441.5 | 462.1 | 427.1 |
| OPM % | 13.58% | 11.78% | 19.24% | 15.75% | 16.06% | 15.76% | 18.77% | 18.75% | 20.58% | 19.01% |
| Other Income | 30.9 | 36.4 | 44.9 | 38.6 | 90.5 | -117.8 | 20.6 | 26.3 | 20.1 | -179.2 |
| Interest | 10.8 | 18.5 | 31.4 | 44.1 | 33.4 | 29.4 | 24.1 | 22.6 | 16.8 | 21.5 |
| Depreciation | 66.6 | 69.5 | 69.3 | 90.3 | 99.5 | 98.1 | 98.9 | 100.4 | 98.5 | 100.1 |
| Profit before tax | 163.5 | 126.5 | 249.7 | 224.4 | 219.2 | 211.7 | 290.4 | 344.8 | 367.0 | 331.3 |
| Tax % | -31.7% | -37.4% | -34% | -39% | -22.9% | -96.2% | -31.5% | -28.8% | -24.6% | -48.6% |
| Net Profit | 109.7 | 78.1 | 164.1 | 136.5 | 221.0 | 1.3 | 199.1 | 245.8 | 276.4 | 64.0 |
| EPS in Rs | 4.25 | 3.02 | 6.42 | 5.72 | 7.09 | 2.35 | 7.58 | 9.05 | 9.78 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 11% |
| 3 Years: | 6% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 6% |
| 3 Years: | -19% |
| TTM: | 44% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 13% |
| 3 Years: | 15% |
| 1 Year: | 10% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 15% |
| 3 Years: | 12% |
| TTM: | 21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 5% |
| 3 Years: | -21% |
| TTM: | 37% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 13% |
| 3 Years: | 15% |
| 1 Year: | 10% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|